Dopamine Receptor Neurons are neurons that express dopamine receptors and respond to dopaminergic signaling. These neurons are critical components of the basal ganglia circuitry, mediating motor control, reward processing, cognition, and motivation. Dysfunction of dopamine receptor signaling is implicated in several neurodegenerative and neuropsychiatric disorders, including Parkinson's Disease, Schizophrenia, and Huntington's Disease.[1]
Dopamine receptors are G protein-coupled receptors (GPCRs) classified into two families based on their pharmacological properties and signaling mechanisms:[2]
These receptor families have distinct anatomical distributions and functional roles in the brain.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000197 | sensory receptor cell |
| Receptor | Primary Regions |
|---|---|
| D1 | Cortex, Striatum, Substantia Nigra pars compacta |
| D2 | Striatum, VTA, cortex |
| D3 | Limbic system, nucleus accumbens |
| D4 | Cortex, hippocampus |
| D5 | Hippocampus, cortex |
D1 receptors are predominantly expressed on direct pathway medium spiny neurons (dMSNs) in the striatum, while D2 receptors are expressed on indirect pathway medium spiny neurons (iMSNs).[3] This segregation forms the basis of the direct and indirect motor pathways.
D1-like Receptor Signaling:
D2-like Receptor Signaling:
| Protein | Interaction | Functional Consequence |
|---|---|---|
| DARPP-32 | PKA substrate | Phosphorylation cascade modulation |
| AKT | PP2A interaction | Cell survival signaling |
| GSK3β | Beta-arrestin complex | Tau phosphorylation |
| mTOR | D2 signaling | Synaptic plasticity |
Dopamine receptor neurons are central to Parkinson's disease pathophysiology:[4]
| Drug Class | Target | Clinical Use |
|---|---|---|
| L-DOPA | D1, D2 | Parkinson's disease |
| Pramipexole | D2/D3 | Parkinson's disease, RLS |
| Ropinirole | D2 | Parkinson's disease |
| Bromocriptine | D2 | Parkinson's disease, hyperprolactinemia |
| Haloperidol | D2 | Schizophrenia |
| Risperidone | D2, 5-HT2 | Schizophrenia |
The dopamine receptor family has been studied extensively since the initial characterization of D1 and D2 receptors in the 1970s. Research has revealed the complexity of dopaminergic signaling and its role in both normal brain function and disease states.
Historical milestones include the development of selective D1 and D2 agonists and antagonists, the discovery of D3-D5 receptors, and the identification of receptor polymorphisms associated with neurological and psychiatric disorders.
Beaulieu JM, et al. Dopamine receptor signaling (2019). 2019. ↩︎
Missale C, et al. Dopamine receptors: from structure to function (2018). 2018. ↩︎
Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function (2008). 2008. ↩︎
Surmeier DJ, et al. The origins of oxidative stress in Parkinson's disease (2017). 2017. ↩︎